27/02/2018
Yuri Kosinsky et al.
J Immunother Cancer. 2018 Feb 27;6(1):17.
•A quantitative systems pharmacology model, which includes key elements of the cancer immunity cycle, tumor growth and dose-exposure-target modulation features, was developed to reproduce experimental data of CT26 tumor size dynamics upon administration of RT and anti-PD-L1 agent.
•The model allowed for a detailed quantitative understanding of the synergistic kinetic effects underlying immune cell interactions as linked to tumor size modulation, under these treatments.
•This study provides quantitative mechanistic explanations of the links between RT and anti-tumor immune response and describes how optimized combinations and schedules of immunomodulation and radiation may tip the immune balance, sufficiently to lead to tumor shrinkage or rejection.
Please, see a more detailed presentation (Kosinsky IO+RT.pdf) and a full text article (JITC (2018) 6, 17_Kosinsky.pdf)
